Abstracts tagged "interferons and myositis"

Abstract Number: 1884 • 2013 ACR/ARHP Annual Meeting
Autoantibody Specificities and Type I Interferon Pathway Activation In Idiopathic Inflammatory Myopathies
Saskia Vosslamber¹, Louise Ekholm², Anna Tjarnlund³, T.D. de Jong¹, Lenka Plestilova⁴, Martin Klein⁵, Peter J. Charles⁶, A.E. Voskuyl⁷, Irene Bultink⁸, Michiel Pegtel¹, J Vencovsky⁹, Ingrid E. Lundberg¹⁰ and Cornelis L. Verweij¹¹, ¹Pathology, VU University Medical Center, Amsterdam, Netherlands, ²Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden, ³Pathology, Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden, ⁴Department of Clinical and Experimental Rheumatology, Institute of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ⁵Institute of Rheumatology, Prague, Prague, Czech Republic, ⁶Oxford University, Kennedy Institute of Rheumatology, Oxford, United Kingdom, ⁷Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ⁸Department of Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ⁹Institute of Rheumatology, Prague, Czech Republic, ¹⁰Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, ¹¹Pathology and Rheumatology, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are rare autoimmune diseases characterized by proximal muscle weakness and muscle inflammation. IIM are associated with several autoantibodies, which are…
Abstract Number: 755 • 2012 ACR/ARHP Annual Meeting
Sifalimumab, an Anti-IFN-Alpha Monoclonal Antibody Shows Target Suppression of a Type I IFN Signature in Blood and Muscle of Dermatomyositis and Polymyositis Patients
Brandon W. Higgs¹, Wei Zhu², Chris Morehouse¹, Wendy White³, Philip Brohawn¹, Charles Le⁴, Anthony A Amato⁵, David Fiorentino⁶, Steven A. Greenberg⁵, Laura Richman¹, Warren Greth⁴, Bahija Jallal¹ and Yihong Yao³, ¹Translational Sciences, MedImmune, LLC, Gaithersburg, MD, ²Translational Science, MedImmune, LLC, Gaithersburg, MD, ³Translational Sciences, MedImmune, Gaithersburg, MD, ⁴Clinical Development, MedImmune, LLC, Gaithersburg, MD, ⁵Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁶Dermatology, Stanford University School of Medicine, Redwood City, CA
Background/Purpose: To assess the pharmacodynamic effects of sifalimumab, an investigational anti-IFN-alpha monoclonal antibody, in the blood and muscle of adult dermatomyositis and polymyositis patients by…
Abstract Number: 218 • 2012 ACR/ARHP Annual Meeting
Proteomics Study of a Phase 1b Trial with an Anti-IFN-α Monoclonal Antibody Indicates Association of Soluble Interleukin 2 Receptor with Type I Interferon Activity in Patients with Dermatomyositis or Polymyositis
Xiang Guo¹, Brandon W. Higgs¹, Wei Zhu², Yihong Yao¹ and Wendy White³, ¹Translational Sciences, MedImmune, LLC, Gaithersburg, MD, ²Translational Science, MedImmune, LLC, Gaithersburg, MD, ³Translational Sciences, MedImmune, Gaithersburg, MD
Background/Purpose: To evaluate downstream effects of an anti-IFN-α monoclonal antibody (mAb) in adult dermatomyositis (DM) and polymyositis (PM) patients using serum proteomics and gene expression…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].